SCHEMBL10282915

SCHEMBL10282915

CC(=O)N1CCC(N)(c2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 3/20 0.55
ALDH1A1 P00352 3/20 0.54
CYP2C19 P33261 3/20 0.54
MAPK1 P28482 3/20 0.54
CYP3A4 P08684 3/20 0.51
CYP2D6 P10635 3/20 0.51
CYP2C9 P11712 2/20 0.51
CYP1A2 P05177 2/20 0.50
HSD17B10 Q99714 2/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50
OPRD1 P41143 1/20 0.49
OPRK1 P41145 1/20 0.49
HIF1A Q16665 1/20 0.49
OPRM1 P35372 1/20 0.49
GAA P10253 1/20 0.48
GFER P55789 1/20 0.48
MEN1 O00255 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10322683 0.86 OPRM1 (0.47) OPRM1MEN1KMT2ASMN1; SMN2
SCHEMBL20491450 0.83 RORC (0.44) USP2ALDH1A1CYP2C19MAPK1CYP2D6
SCHEMBL18088638 0.81 USP2 (0.57) USP2ALDH1A1CYP2C19MAPK1CYP3A4
SCHEMBL10515682 0.81 USP2 (0.57) USP2ALDH1A1CYP2C19MAPK1CYP3A4
SCHEMBL7975314 0.80 HSD11B1 (0.55) USP2ALDH1A1CYP2C19MAPK1CYP3A4
SCHEMBL22874143 0.80 APP (0.56) OPRD1OPRK1OPRM1GAA
SCHEMBL13774957 0.79 CA12 (0.59) USP2ALDH1A1CYP2C19MAPK1CYP3A4
SCHEMBL6159810 0.79 OPRM1 (0.42) MAPK1OPRM1KMT2A
SCHEMBL10324681 0.79 TSHR (0.56) OPRD1OPRK1
Hydrochloric Acid SCHEMBL3595461 0.78 MAOA (0.56) USP2ALDH1A1CYP2C19MAPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090186874-A1 Carboxamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-07-23 US disclosed
US-20090186874-A1 Carboxamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186874-A1 Carboxamide derivative and use thereof NTSR2, NTSR1, CNR2 USP2 3605/4885ALDH1A1 2419/4885CYP2C19 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.